Načítá se...
Efficacy of Evolocumab in Monogenic vs Polygenic Hypercholesterolemia
BACKGROUND: Inhibitors of proprotein convertase subtilisin kexin 9 are indicated in Canada for treatment of patients with familial hypercholesterolemia (FH). Classically, FH is considered to be a monogenic condition caused by rare pathogenic mutations; however, some patients have hypercholesterolemi...
Uloženo v:
| Vydáno v: | CJC Open |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Elsevier
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7063626/ https://ncbi.nlm.nih.gov/pubmed/32159093 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cjco.2019.02.005 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|